Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;33(12):2974-2978.
doi: 10.1038/s41375-019-0524-7. Epub 2019 Jul 30.

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

J Mascarenhas  1 , H Kosiorek  2 , J Prchal  3 , A Yacoub  4 , D Berenzon  5 , M R Baer  6 , E Ritchie  7 , R T Silver  7 , C Kessler  8 , E Winton  9 , M C Finazzi  10 , A Rambaldi  10   11 , A M Vannucchi  12 , D Leibowitz  13 , D Rondelli  14 , M O Arcasoy  15 , R Catchatourian  16 , J Vadakara  17 , V Rosti  18 , E Hexner  19 , M Kremyanskaya  20 , L Sandy  20 , J Tripodi  21 , V Najfeld  21 , N Farnoud  22 , M E Salama  23 , R S Weinberg  24 , R Rampal  22 , J D Goldberg  25 , R Mesa  26 , A C Dueck  2 , R Hoffman  20
Affiliations

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

J Mascarenhas et al. Leukemia. 2019 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
1A Oncoprint of identified genomic alterations in 17 baseline samples. Individual genes are represented as rows, and the patients are represented as columns. The bars at the top of the figure indicate the number of somatic alterations that were identified in the corresponding patient at baseline. Different colors distinguish the type of alterations, such as missense (dark blue), stop-gain (black), in-frame indel (light blue), and frameshift indel (red). The genes (rows) are sorted based on the frequency of the gene-level alterations in the cohort, as noted on the left of the figure. The best clinical response of each patient is displayed at the bottom annotation bar according to the key. 1B JAK2V617F variant allele fraction (VAF) waterfall plot. The y-axis indicates absolute change from the baseline VAF. Each bar represents an individual patient and the colors denote best response status (red: CR, green: PR and blue: NR). The stars highlight patients who have significant change of VAF from baseline. These is a subset of patients for whom the 95% confidence interval of VAF (with respect to the depth of coverage of the mutation in corresponding sample) did not overlap between baseline and last time-points.
See this image and copyright information in PMC

References

    1. Papadakis E, Hoffman R, Brenner B. Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev. 2010;24(6):227–32. - PubMed
    1. De Stefano V, Qi X, Betti S, Rossi E. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb Haemost. 2016;115(2):240–9. - PubMed
    1. Schulman S Splanchnic vein thrombosis: what are the long-term risks? Lancet Haematol. 2018;5(10):e431–e2. - PubMed
    1. De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larran A, Iurlo A, et al. Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J. 2016;6(11):e493. - PMC - PubMed
    1. Lavu S, Szuber N, Mudireddy M, Yogarajah M, Gangat N, Pardanani A, et al. Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases. Am J Hematol. 2017. - PubMed

Publication types

MeSH terms